Strides Shasun has received approval from the United States Food & Drug Administration (USFDA) for Potassium Citrate Extended-Release Tablets USP, 5 mEq, 10 mEq, and 15 mEq.

According to IMS data, the US market for Potassium Citrate is approximately USD 110 million.

The company will be the second generic player to commercialize the product. The product, which is the first approval for an Extended Release tablet for the company, will be launched immediately.

Potassium Citrate, a urinary alkalinizing agent, is used for preventing certain types of kidney stones. It works by neutralizing some of the acid in the urine, which helps reduce the formation of crystals. 

Shares of the company gained Rs 28.7, or 3.05%, to trade at Rs 970.00. The total volume of shares traded was 46,320 at the BSE (9.58 a.m., Tuesday).